Federal regulators Tuesday threatened cannabis giant Curaleaf with possible legal action for allegedly making unsubstantiated medical claims about the cannabidiol, or CBD, products on its website and on social media.
In a public letter, the U.S. Food and Drug Administration gave Massachusetts-based Curaleaf about two weeks to explain what it has done to correct alleged violations, including website claims that CBD has “properties that counteract the growth of spread of cancer” and is “linked to the effective treatment of Alzheimer’s disease.”
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]